News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immune Pharmaceuticals, Inc. Announces Phase 3 Development And Commercialization Strategy For AMIKET


5/5/2014 9:10:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK and HERZLIYA-PITUACH, Israel, May 5, 2014 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals Inc. (OTCQX: IMNP) (Nasdaq:IMNP) ("Immune" or the "Company") announces its clinical trial and commercialization strategy for AmiKet, a topical drug for the treatment of Neuropathic Pain, pursuant to which the Company is ready to advance to phase 3 clinical trials, based on nine clinical trials in a total of 1700 patients. AmiKet is a topical combination of amitryptiline and ketamine designed to reduce the pain of patients with Post Herpetic Neuralgia (PHN), Diabetic Peripheral Neuropathy (DPN) and Chemotherapy Induced Neuropathic Pain (CIPN).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES